In the present report, investigations have been carried out to evaluate toxic and therapeutic effects of cyclophosphamide vs its isomer iphosphamide. Cytostatic action of the 2 drugs was assayed on the murine Lewis lung carcinoma (3LL). It has been observed that iphosphamide is less toxic as compared to cyclophosphamide ; on the other hand, to reach the same therapeutic effectiveness on 3LL, an iphosphamide dose 1.6 - 2 times higher than that of its parent compound is necessary.
Get full access to this article
View all access options for this article.
References
1.
AlarconR.A., MeienhoferJ., AthertonE.: Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide.Cancer Res.,32: 2519–2523, 1972.
2.
BrockN.: Pharmakologische Untersuchungen mit neuen N-chlorathyl-phosphor-saureester-diamiden. pp. 155–161. In: Proceedings of the 5th International Congress of Chemotherapy. Vol. 2, SpitzyK.H., and HaskekH., Vienna, 1972.
3.
CarterS.K., SchabelF.M.Jr., BroderL.E., JohnstonT.P.: 1,3-Bis (2-chloroethyl)-1-nitrosourea (BCNU) and other nitrosoureas in cancer treatment: A review. pp. 273–332. In: Advances in Cancer Research. Vol. 2, KleinG., and WeinhouseS. (eds.), New York-London, 1972.
4.
CohenM.H., MittlemanA.: Initial clinical trials with ifosfamide.Proc. Am. Soc. Cancer Res.,14: 64, 1973.
5.
CostanziJ.J., GaglianoR., LoukasD., PanettiereF.J., HokansonJ.A.: Ifosfamide in the treatment of recurrent or disseminated lung cancer. A phase II study of two dose schedules.Cancer,41: 1715–1719, 1978.
6.
CreavenP.J., AllenL.M., CohenM.H., NelsonR.L.: Studies on the clinical pharmacology and toxicology of isophosphamide.Cancer Treat. Rep.,60: 445–451, 1976.
7.
De WysW.D.: A quantitative model for the study of the growth and treatment of a tumor and its metastases with correlation between proliferative state and sensitivity to cyclophosphamide.Cancer Res.,32: 367–373, 1972.
8.
GeranR.I., GreenbergN.H., MacDonaldM.M., SchumacherA.M., AbbottB.J.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems.Cancer Chemother. Rep.,3: 1–103, 1972.
9.
GoldinA.: Effects of drugs on disseminated tumor. pp. 341–354. In: Chemotherapy of Cancer Dissemination and Metastasis.GarattiniS., and FranchiG. (eds.). New York, 1973.
10.
LelieveldP., Van PuttenL.M.: Biologic activity of two derivatives and six possible metabolites of cyclophosphamide.Cancer Treat. Rep.,60: 373–379, 1976.
11.
LitchfieldJ.T., WilcoxonF.: A simplified method of evaluating dose-effect experiments.J. Pharmacol. Exp. Ther.,96: 99–113, 1949.
12.
MayoJ.G.: Biologic characterization of the subcutaneously implanted Lewis lung tumor.Cancer Chemother. Rep.,3: 325–330, 1972.
RodriguezV., BodeyG.P., FreireichE.J., McCredieK.B., McKelveyE.M., TashimaC.K.: Reduction of iphosphamide toxicity using dose-fractionation.Cancer Res.,36: 2945–2948, 1976.
15.
SchabelF.M.Jr.: Concepts for systemic treatment of micrometastases.Cancer,35: 15–24, 1975.
16.
SchabelF.M.Jr.: Surgical adjuvant chemotherapy of metastatic murine tumors.Cancer,40: 558–568, 1977.
17.
Simpson-HerrenL., LloydH.H.: Kinetic parameters and growth curves for experimental tumor systems.Cancer Chemother. Rep.,54: 143–174, 1970.
18.
SteelG.G., AdamsK.: Stem-cell survival and tumor control in the Lewis lung carcinoma.Cancer Res.,35: 1530–1575, 1975.
19.
Von ArdenneM., ReitnauerP.G., RhodeK.: Vergleich von Ifosfamid mit Cy-clophosphamid bei der Therapie des DS-Karzinosarkoms der Ratte.Arch. Geschwulstforsch,38: 15–26, 1971.
20.
WexlerH.: Accurate identification of experimental pulmonary metastases.J. Nat. Cancer Inst.,36: 641–645, 1966.
